Physician profile
David Patrick Kennedy
NPI 1518258755
$5,438.48
in general payments reported to CMS, 2019-2025
29 companies · $1,136 in 2025
The $1,136 reported for 2025 was more than what 80% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $595 · 2020: $168 · 2021: $675 · 2022: $629 · 2023: $1,113 · 2024: $1,124 · 2025: $1,136.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,372.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,372.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaukos Corporation | $986.89 | 2019-2025 | Kxl System (Not Refurbished), Kxl1b-Ce-Marked Kxlsystem, Istent Infinite Trabecular Micro-Bypass System Model Is3 |
| Alcon Vision LLC | $971.52 | 2019-2025 | Rocklatan, Clareon, Clareon Panoptix Pro |
| Tarsus Pharmaceuticals, INC. | $392.35 | 2024-2025 | Xdemvy |
| Biotissue Holdings INC. | $317.17 | 2019-2025 | |
| Abbvie INC. | $306.84 | 2022-2025 | |
| Rxsight INC | $272.35 | 2024 | Rxsight Contact Lens, Rxsight Injector Cartridge, Light Adjustable Lens (Lal) |
| Dompe US, INC. | $248.49 | 2019-2025 | Oxervate |
| Oyster Point Pharma, INC. | $214.64 | 2022-2025 | Tyrvaya, Ryzumvi |
| Carl Zeiss Meditec USA, INC. | $206.45 | 2021 | |
| Allergan, INC. | $189.94 | 2019-2022 | |
| Mallinckrodt Hospital Products INC. | $163.72 | 2022-2025 | Acthar |
| Lumenis Be INC | $156.81 | 2022 | |
| Novartis Pharmaceuticals Corporation | $144.63 | 2019-2023 | |
| Bausch & Lomb Americas INC. | $137.61 | 2023-2025 | Miebo, Xiidra, Envista Mx60 Iol |
| Sun Pharmaceutical Industries INC. | $135.44 | 2019-2023 | Cequa |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eyevance Pharmaceuticals LLC | $100.91 | 2019-2022 | |
| Johnson & Johnson Surgical Vision, INC. | $91.40 | 2023 | Tecnis Iol, Catalys System |
| Harrow Eye, LLC | $75.24 | 2024-2025 | Vevye |
| Ocular Therapeutix, INC. | $66.21 | 2023-2024 | Dextenza |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $58.58 | 2019-2021 | |
| Aerie Pharmaceuticals, INC. | $37.69 | 2019-2021 | |
| Ani Pharmaceuticals, INC. | $31.21 | 2025 | Purified Cortrophin Gel |
| Coopervision INC. | $30.40 | 2022-2025 | Biofinity Contact Lens |
| Shire North American Group INC | $20.47 | 2019 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Rayner Intraocular Lenses Limited | $18.46 | 2022 | |
| Horizon Therapeutics Plc | $16.92 | 2023 | Tepezza |
| New World Medical,INC. | $16.59 | 2025 | Ahmed Glaucoma Valve, Clearpath, Kahook Dual Blade |
| Heidelberg Engineering, INC. | $10.15 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Kennedy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.